Innocan Pharma Reports 9.6% Revenue Decline to $26.6M in 2025, Eyes U.S. Public Offering
INNPF is trading near its 52-week low of $4.34 (14% above the low) on light trading volume (0.2× avg).
Summary
Innocan Pharma reported its audited financial results for the year ended December 31, 2025, with revenues decreasing by 9.6% to $26.6 million and gross profit declining by 8.6% to $23.9 million. Despite the revenue contraction, the company maintained a high gross margin of 89.9% and a stable operating loss of $1.255 million. Management commentary highlighted improving sales trends carrying into Q1 2026 and announced significant progress towards a U.S. public offering. This annual financial update provides key performance indicators for the small-cap company, revealing a revenue decline but also strategic initiatives and a positive outlook on future growth and capital market access.
At the time of this announcement, INNPF was trading at $4.95 on OTC in the Life Sciences sector, with a market capitalization of approximately $22.3M. The 52-week trading range was $4.34 to $82.59. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.